Bluebird Bio Flies; Blood Cancer Drug Impresses In Small Trial

Two biotech stocks are climbing today thanks to the results of one small drug trial testing a new type of treatment for multiple myeloma Bluebird bio ( BLUE ) surged more than 18% today after data from a Phase 1 study released late Wednesday showed that patients suffering from the blood cancer multiple myeloma who had failed to show improvement from repeated treatments with existing therapies showed strong benefits from the drug called bb2121 that it is develop in partnership with Celgene ( CELG ). Celgene shares climbed 0.5% today.